EICHORPublic-registry trials using HTD1801 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
HTD1801 appears in 1 registered trial Eichor's radar has found, sponsored by HighTide Biopharma Pty Ltd, the most recent registered as Phase 2, with a planned enrollment of 218. Registered timeline: 2022–2025. The registry holds 11,837 registered studies for Type 2 Diabetes.
| Trial | Sponsor | Condition | Phase | Sites |
| HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes | HighTide Biopharma Pty Ltd | Nonalcoholic Steatohepatitis (NASH) | PHASE2 | 45 |
| Status | Completed · planned start 2022-12 |
| Primary completion | 2025-04 |
| Enrollment target | 218 participants |
| Design | Randomized · Sequential · Phase 2 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 45 listed in Hong Kong, Puerto Rico, United States |
All fields verbatim from the ClinicalTrials.gov record for NCT05623189.
| First registered study | April 2017 — NCT03099603 (HighTide Therapeutics (Hong Kong) Limited) |
| Registered studies matching this name | 12 all-time · 1 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 11,837 registered studies for Type 2 Diabetes. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Nonalcoholic Steatohepatitis (NASH) drugs
← Eichor home · All tracked trials · Nonalcoholic Steatohepatitis (NASH) studies · Weekly briefs
